Abstract
Regionally-administered, drug-loaded microspheres have a potential role in the treatment of renal tumours. Vasoactive agents, for example, angiotensin II, may allow selective delivery of microspheres to tumour. The present study defines the regional advantage that may be obtained from angiotensin II by quantifying tumour and normal kidney blood flow using radiolabelled microsphere renal perfusion studies and per-operative laser-doppler flow measurements. Angiotensin II increased microsphere distribution to tumour, relative to normal kidney, by a factor of four. This enhancement was associated with an absolute increase in tumour blood flow.
Highlights
Renal carcinoma accounts for 2-3% of all adult malignancies
The majority of patients have no evidence of metastases at the time of initial presentation (Patel & Lavengood, 1978); nephrectomy is the treatment of choice
We have previously shown that the selective administration of cytotoxic-loaded albumin microspheres via the renal artery produces high concentrations of drug within the kidney (McArdle et al, 1988; Kerr et al, 1988)
Summary
A 57 year old male presented with lower abdominal pain and constipation. Barium enema examination failed to show any colonic pathology. The patient was prepared for renal angiography to be followed by nephrectomy
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
